title: Neoadjuvant chemotherapy for primary adenocarcinomas of the urinary bladder: a single-site experience.
abstract: BACKGROUND
  Adenocarcinoma of the urinary bladder is a rare malignancy. Radical surgery is suggested as the best available treatment for early-stage disease, but there is currently no consensus on standard chemotherapy regimen for advanced stage. We assessed the feasibility and effect of neoadjuvant chemotherapy with gemcitabine and cisplatin (GC) plus S-1 for patients with locally advanced primary adenocarcinomas of the urinary bladder.
  
  
  METHODS
  Six patients with locally advanced urachal or non-urachal (n = 3, each) primary adenocarcinoma of the bladder were treated from October 2010 to October 2013 at a single center. All the patients were treated with 3 cycles (21d, each) of GC plus S-1 (gemcitabine, 1000 mg/m2, days 1 and 8; cisplatin, 70 mg/m2, day 2; and S-1, 50 mg bid, day 1-14). After neoadjuvant chemotherapy, patients with urachal cancer were treated with en bloc radical cystectomy and umbilectomy; the remaining 3 patients were treated with cystectomy.
  
  
  RESULTS
  All patients successfully completed the neoadjuvant chemotherapy without serious side effects. Two patients were assessed as complete response, 2 as partial response, 1 as stable disease and 1 as progressive disease.
  
  
  CONCLUSIONS
  Despite the limitations of a small study population, the GC plus S-1 regimen for locally advanced primary adenocarcinoma of the urinary bladder was effective, and facilitated the success of surgery to a certain extent. Short follow-up time was also a limitation of our study. More studies are needed to evaluate the results.
authors: Bin
authors: B
authors: Yu
authors: Jin
authors: J
authors: Zhou
authors: Hongzhou
authors: H
authors: Cai
authors: Ting
authors: T
authors: Xu
authors: Zicheng
authors: Z
authors: Xu
authors: Department of Urologic Surgery, Affiliated Cancer Hospital of Jiangsu Province of Nanjing Medical University, Nanjing, China. 343463975@qq.com.
authors: Qing
authors: Q
authors: Zou
authors: Min
authors: M
authors: Gu
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D011446:Prospective Studies; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D003841:Deoxycytidine; D002945:Cisplatin; D000093542:Gemcitabine
references: Clin Pharmacokinet. 2013 Dec;52(12):1085-100
references: 23818090
references: Int Urol Nephrol. 2013 Feb;45(1):107-11
references: 23054322
references: J Clin Oncol. 2000 Sep;18(17):3068-77
references: 11001674
references: J Urol. 2003 Apr;169(4):1295-8
references: 12629346
references: Eur Urol. 2003 Dec;44(6):672-81
references: 14644119
references: South Med J. 1972 May;65(5):527-30
references: 5027455
references: Urology. 1985 Sep;26(3):252-5
references: 3929441
references: Expert Rev Anticancer Ther. 2006 Dec;6(12):1715-21
references: 17181485
references: Urology. 2007 Jan;69(1 Suppl):93-104
references: 17280911
references: N Engl J Med. 2008 Jan 3;358(1):36-46
references: 18172173
references: Ann Oncol. 2009 Apr;20(4):666-73
references: 19153121
references: Expert Rev Anticancer Ther. 2009 Jun;9(6):821-30
references: 19496719
references: Eur Urol. 2009 Feb;55(2):348-58
references: 18977070
references: J Urol. 2010 Mar;183(3):915-20
references: 20083267
references: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references: 21296855
references: Cancer Imaging. 2012;12:345-6
references: 23023096
references: Drug Metabol Personal Ther. 2015 Mar;30(1):33-41
references: 25252750